Surgery, Gastroenterology and Oncology
Vol. 26, No. 4, Dec 2021
Evaluation of Metabolic Syndrome as A Risk Factor for Colorectal Cancer
A. Bahnasy, Rawhia Hassan El-Edel, Hanaa El sayed Ahmed Barakat, Abd El Naser Abd El Atty Gadallah
ORIGINAL PAPER, Dec 2021
Article DOI: 10.21614/sgo-26-4-420
Objective: This study was designed to determine the relationship between metabolic syndrome as a risk factor for colorectal cancer.

Background: Overweight and obesity are leading risks for global deaths. Although the increase in obesity over the last 35 years has been most dramatic in the US and western industrialized countries, similar trends have also been seen in urban areas of many developing countries. There are multiple common health consequences of an elevated body mass index, including risk for several metabolic disorders, some cancers and ultimately increased mortality.

Patients and methods: A case control study was carried out on 150 patients 100 cases with colorectal cancer (CRC), and 50 healthy age and sex matched controls. The patients were randomly selected from those attending Gastroenterology Unit in Menoufia University Hospital and Kafr el sheikh University Hospital, Egypt during April 2019 till February 2020. All subjects included in this study divided into Group I included100 patients with (CRC) with colorectal cancer diagnosed based on pathological results and Group II included 50 normal healthy subjects of matched age and sex served.

Results: There was no statistically significant differences between the studied groups regarding gender (p=0.074), and age year (p=0.162). While, Insulin-like growth factor-1 level and carcinoembryonic antigen were significantly higher among colorectal cancer patients than control groups (p<0.05).

Conclusion: Metabolic syndrome (MetS) is a state of chronic low-grade inflammation as a consequence of complex interplay between genetic and environmental factors.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 2240


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.